Please login to the form below

Not currently logged in
Email:
Password:

Imfinzi

This page shows the latest Imfinzi news and features for those working in and with pharma, biotech and healthcare.

FDA advisory committee to review oncology accelerated approvals

FDA advisory committee to review oncology accelerated approvals

AZ also recently announced that it would withdraw Imfinzi’s indication for advanced bladder cancer after a post-marketing study failed to hit the mark.

Latest news

More from news
Approximately 27 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Cancer therapies Tagrisso (osimertinib) – now AZ’s top-selling drug – Lynparza (olaparib) and Imfinzi (durvalumab) are already gathering momentum, as they rack up additional indications that extend their use and there ... checkpoint inhibitor

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    Now the business has two particularly strong growth drivers: emerging markets, most especially China, and oncology, where a triumvirate of drugs – Tagrisso, Imfinzi and Lynparza – have hit a major growth phase.

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... Of course, AstraZeneca isn’t immune to the setbacks of old –

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the setback to its Imfinzi tremelimumab immunotherapy combination in the MYSTIC lung cancer trial last year –

More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...